Скачать или смотреть IMA203, a PRAME-directed TCR therapy, shows promise in uveal melanoma

Marco Donia, MD, PhD, Copenhagen University Hospital, Herlev, Denmark, discusses results and the significance of the Phase Ia/b trial (NCT03686124/EudraCT 2019-002370-31), which assessed IMA203, a PRAME-directed T-cell receptor therapy, in pre-treated patients with advanced or metastatic uveal melanoma. The therapy demonstrated a high objective response rate and durable responses. Despite the complex treatment regimen and significant toxicities, this treatment is very promising due to its curative potential. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.